April 6, 2026
Experts discuss novel biomarkers like microRNA-371 for de-escalating therapy and new targets like Claudin-6 for refractory germ cell tumors.
March 30, 2026
Experts debate systemic therapy alone for MIBC. Is the EV209 trial's bladder-sparing approach safe? Key concerns on cycles & endpoints.
March 8, 2026
ASCO GU recap: Bladder cancer revolutionizes with EV-Pembro, kidney cancer advances with new combos, while prostate cancer awaits its next wave.
March 4, 2026
ctDNA is transforming perioperative bladder cancer care, with positivity and clearance rates emerging as powerful prognostic biomarkers to guide therapy.
February 28, 2026
LITESPARK 022 shows Adjuvant Pembro + Belzutifan significantly improves DFS in RCC, sparking debate on toxicity, OS trends, and clinical impact.
LITESPARK-011 trial: Belzutifan/Lenvatinib combo tops Cabozantinib in refractory kidney cancer with superior PFS and durable responses.
SUNRISE 2 trial stopped for futility as TAR-200 combo fails to beat chemoradiation in MIBC, sparking debate on patient selection.
February 27, 2026
KEYNOTE B15 shows Neoadjuvant EVP beats Gem/Cis in cis-eligible MIBC, improving EFS, OS, and Path CR, setting a new standard of care.
February 26, 2026
Dr. Evan Yu unpacks final OS data from PEACE-3 (Radium+Enza) and BRCAway (PARPi+Abi), detailing their impact on radioligand and PARP use.
February 23, 2026
Experts deconstruct a controversial study on immunotherapy timing, highlighting major flaws in its data, methodology, and peer-review process.
February 16, 2026
PCWG 4 updates prostate cancer trial criteria with new patient-centric nomenclature, revised PSMA PET imaging rules, and biomarker integration.
February 9, 2026
Experts preview ASCO GU 2026, highlighting pivotal Phase III trials for kidney (Belzutafan), bladder (EV-Pembro), and prostate cancer.
February 2, 2026
FDA analysis of mRCC trials shows deeper tumor shrinkage continuously predicts better survival, with no clear threshold and differences by regimen.
January 26, 2026
Experts discuss IO & ADC re-challenge in urothelial cancer, a data-free zone where patient selection and prior response are key considerations.
January 19, 2026
The EMBARK trial's impressive MFS/OS data in BCR prostate cancer face new challenges from PSMA PET imaging and questions on trial design.
January 12, 2026
Experts discuss managing variant histology bladder cancer, highlighting when to alter therapy for pure variants vs. using EV+Pembro for mixed types.
January 5, 2026
Experts discuss the next wave of prostate cancer therapies: bispecific T-cell engagers (BiTEs) and ADCs, detailing ongoing Phase 3 trials.
December 29, 2025
2025 was a 10/10 year for bladder cancer. EV-Pembro transforms MIBC, new ADCs emerge, and ctDNA refines adjuvant care. A deep dive review.
December 22, 2025
Prostate cancer experts review 2025's key trials, highlighting the rise of personalized therapy, the need for better patient selection, and chemotherapy's enduring value.
December 15, 2025
Uromigos podcast recaps 2025 kidney cancer data: the Rampart study reinforces adjuvant IO, Kim1 shows biomarker promise, and combos advance.
December 9, 2025
Experts use the Uromigos score to rank bladder cancer treatments, revealing a consensus shift towards ADC-based combos as the new standard of care.
November 24, 2025
Experts discuss the transformative journey of ARPIs in prostate cancer, from pivotal trials to future de-intensification strategies.
November 10, 2025
Experts debate adjuvant kidney cancer therapy, dissecting KEYNOTE-564's survival benefit, RAMPART's promise, and LITESPARK-022's surprising data.
Experts debate adding a third agent to the mHSPC backbone, weighing docetaxel, PARP inhibitors, and lutetium based on new trial data.
November 8, 2025
Experts debate the PSMA-addition trial for radioligand therapy in prostate cancer, weighing early RPFS gains against toxicity and trial design.
Mock ODAC debates immunotherapy for bladder cancer. Do modest efficacy gains from cisanlimab & durvalumab justify significant toxicity risks?
November 7, 2025
Experts debate DV-Toripalumab's impact on urothelial cancer, comparing it to EV-Pembro and questioning HER2 biomarkers and future ADC sequencing.
Experts debate the transformative EV Pembro trial for bladder cancer, signaling a shift to neoadjuvant therapy and questioning surgery's future role.
